Dr Katy Bell

NHMRC Senior Research Fellow
Public Health, School of Public Health

Telephone 0415 764 321
Fax 9351 7420

Map

Biographical details

Cancers and other non-infectious chronic diseases such as cardiovascular disease are leading causes of morbidity and pre-mature mortality in adult populations worldwide and testing for these conditions accounts for a large proportion of health expenditure. I am a medically trained epidemiologist with expertise in the evaluation of tests used for screening, diagnsosis and monitoring. My research aims to optimise test use in each of these phases in order to maximise benefits and minimise harms on clinically relevant outcomes.

Research interests

Evaluation of benefits and harms of tests used for screening, diagnostic and monitoring people with chronic disease. Examples of chronic diseases where I have examined test use already, and /or are under current study, include: cardiovascular disease, osteoporosis, osteoarthritis, melanoma, prostate, breast, thyroid and lung cancer.

Teaching and supervision

I am a Tutor for the Clinical Epidemiology Program, School of Public Health, University of Sydney for the units on Diagnostic and Screening Tests (Introductory and Advanced) and Introduction to Systematic Reviews.

Current projects

In my current capacity as senior research fellow within the Wiser Healthcare collaboration (http://wiserhealthcare.org.au/ ), I am leading a number of collaborative research projects relating to overdiagnosis (both primary studies and new analysis of existing datasets). I am also leading several primary studies conducted in patients with melanoma, including a pilot randomised controlled trial of surveillance methods; an observational study (questionnaire and phone interview), and a qualitative study. Other studies I am leading include methodological studies related to estimating cardiovascular risk, long term effects of interventions to prevent cardiovascular disease, and the population impact of interventions.

Awards and honours

  • BUPA Emerging Health Researcher 2016 Commendation Award
  • Winner of 2015 Australasian Epidemiological Association Early Career Researcher Travel Award
  • University of Otago Award in Medicine (for outstanding academic achievement in medical degree) 

Selected grants

2016

  • Katy Bell Bridging Support Grant; Bell K; DVC Research/Bridging Support Fellowship.

2011

  • Optimising the monitoring of cardiovascular risk; Bell K; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Bell, K., Craig, J., Irwig, L. (2008). Monitoring the initial response to treatment. In P Glasziou, L Irwig and J K Aronson (Eds.), Evidence-based Medical Monitoring:From Principles to Practice, (pp. 75-89). Oxford: Blackwell Publishers.

Journals

  • Bell, K., Hayen, A., Glasziou, P., Irwig, L., Bauer, D. (2017). Change in bone mineral density is an indicator of treatment-related antifracture effect. Annals of Internal Medicine, 166(2), 152-152. [More Information]
  • Jansen, J., McKinn, S., Bonner, C., Irwig, L., Doust, J., Glasziou, P., Bell, K., Naganathan, V., McCaffery, K. (2017). General practitioners' decision making about primary prevention of cardiovascular disease in older adults: A qualitative study. PloS One, 12(1), 1-13. [More Information]
  • Bell, K., Hayen, A., Glasziou, P., Irwig, L., Eastell, R., Harrison, S., Black, D., Bauer, D. (2016). Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. Journal of Bone and Mineral Research, 31(9), 1767-1773. [More Information]
  • Furuya-Kanamori, L., Bell, K., Clark, J., Glasziou, P., Doi, S. (2016). Prevalence of differentiated thyroid cancer in autopsy studies over six decades: A meta-analysis. Journal of Clinical Oncology, 34(30), 3672-3679. [More Information]
  • Bell, K., Bossuyt, P., Glasziou, P., Irwig, L. (2015). Assessment of changes to screening programmes: why randomisation is important. BMJ, 350, 1-4. [More Information]
  • Memari, N., Hayen, A., Bell, K., Rychetnik, L., Morton, R., McCaffery, K., Thompson, J., Irwig, L., Turner, R. (2015). How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center? Annals of Surgical Oncology, 22(Supp 3), 1164-1171. [More Information]
  • Bell, K., Del Mar, C., Wright, G., Dickinson, J., Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. International Journal of Cancer, 137(7), 1749-1757. [More Information]
  • Bell, K., McCaffery, K., Irwig, L. (2015). Screening tests for gonorrhoea should first do no harm. Medical Journal of Australia, 202(6), 281-282. [More Information]
  • Bell, K., Beller, E., Sundstrom, J., McGeechan, K., Hayen, A., Irwig, L., Neal, B., Glasziou, P. (2014). Ambulatory blood pressure adds little to Framingham Risk Score for the primary prevention of cardiovascular disease in older men: secondary analysis of observational study data. BMJ Open, 4(9), 1-9. [More Information]
  • Bell, K., Glasziou, P., Hayen, A., Irwig, L. (2014). Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality. Journal of Clinical Epidemiology, 67(2), 152-159. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Takahashi, O., Ohde, S., Glasziou, P. (2013). When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ, 346(7906), 1-8. [More Information]
  • Hayden, A., Bell, K., Glasziou, P., Irwig, L. (2012). A counterargument to encounter frequency and target achievement: measurement variability. Archives of Internal Medicine, 172(4), 374-375. [More Information]
  • Bell, K., Hayen, A., McGeechan, K., Neal, B., Irwig, L. (2012). Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. European Journal of Preventive Cardiology, 19(6), 1474-1485. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Hochberg, M., Ensrud, K., Cummings, S., Bauer, D. (2012). The Potential Value of Monitoring Bone Turnover Markers Among Women on Alendronate. Journal of Bone and Mineral Research, 27(1), 195-201. [More Information]
  • Bell, K., Kirby, A., Hayen, A., Irwig, L., Glasziou, P. (2011). Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ: British Medical Journal, 342(7791), 1-7. [More Information]
  • Turner, R., Bell, K., Morton, R., Hayen, A., Francken, A., Howard, K., Armstrong, B., Thompson, J., Irwig, L. (2011). Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 29(35), 4641-4646. [More Information]
  • Hayen, A., Bell, K., Glasziou, P., Neal, B., Irwig, L. (2010). Monitoring Adherence to Medication by Measuring Change in Blood Pressure. Hypertension, 56(4), 612-616. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Fox, K., Remme, W., Asselbergs, F., van Gilst, W., MacMahon, S., Irwig, L., et al (2010). Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials. Hypertension, 56(3), 533-539. [More Information]
  • Bell, K., Irwig, L., Hayen, A., Macaskill, P., Craig, J. (2010). Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers. Pharmacoepidemiology and drug safety, 19(1), 99-105. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Macaskill, P., Craig, J., Ensrud, K., Bauer, D. (2010). The Value of Routine BMD Monitoring After Starting Bisphosphonate Treatment. Journal of Bone and Mineral Research, 25(1), 173-174. [More Information]
  • Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? A prospective study. Asia-Pacific Journal of Clinical Oncology, 5(4), 257-263. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Irwig, L. (2009). Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. Journal of Clinical Epidemiology, 62, 650-659. [More Information]
  • Lincz, L., Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Thrombin generation as a predictor of radiotherapy induced skin erythema. Radiotherapy and Oncology, 90(1), 136-140. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Irwig, L., Craig, J., Ensrud, K., Bauer, D. (2009). Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ: British Medical Journal, 338(7710), 1-5. [More Information]
  • Bell, K., Irwig, L., Craig, J., Macaskill, P. (2008). Use of randomised trials to decide when to monitor response to new treatment. BMJ: British Medical Journal, 336, 361-365. [More Information]
  • Bell, K., Wattie, M., Byth Wilson, K., Silvestrini, R., Clark, P., Stachowski, E., Benson, E. (2003). Procalcitonin: A marker of bacteraemia is SIRS. Anaesthesia and Intensive Care, 31(6), 629-636.

2017

  • Bell, K., Hayen, A., Glasziou, P., Irwig, L., Bauer, D. (2017). Change in bone mineral density is an indicator of treatment-related antifracture effect. Annals of Internal Medicine, 166(2), 152-152. [More Information]
  • Jansen, J., McKinn, S., Bonner, C., Irwig, L., Doust, J., Glasziou, P., Bell, K., Naganathan, V., McCaffery, K. (2017). General practitioners' decision making about primary prevention of cardiovascular disease in older adults: A qualitative study. PloS One, 12(1), 1-13. [More Information]

2016

  • Bell, K., Hayen, A., Glasziou, P., Irwig, L., Eastell, R., Harrison, S., Black, D., Bauer, D. (2016). Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. Journal of Bone and Mineral Research, 31(9), 1767-1773. [More Information]
  • Furuya-Kanamori, L., Bell, K., Clark, J., Glasziou, P., Doi, S. (2016). Prevalence of differentiated thyroid cancer in autopsy studies over six decades: A meta-analysis. Journal of Clinical Oncology, 34(30), 3672-3679. [More Information]

2015

  • Bell, K., Bossuyt, P., Glasziou, P., Irwig, L. (2015). Assessment of changes to screening programmes: why randomisation is important. BMJ, 350, 1-4. [More Information]
  • Memari, N., Hayen, A., Bell, K., Rychetnik, L., Morton, R., McCaffery, K., Thompson, J., Irwig, L., Turner, R. (2015). How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center? Annals of Surgical Oncology, 22(Supp 3), 1164-1171. [More Information]
  • Bell, K., Del Mar, C., Wright, G., Dickinson, J., Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. International Journal of Cancer, 137(7), 1749-1757. [More Information]
  • Bell, K., McCaffery, K., Irwig, L. (2015). Screening tests for gonorrhoea should first do no harm. Medical Journal of Australia, 202(6), 281-282. [More Information]

2014

  • Bell, K., Beller, E., Sundstrom, J., McGeechan, K., Hayen, A., Irwig, L., Neal, B., Glasziou, P. (2014). Ambulatory blood pressure adds little to Framingham Risk Score for the primary prevention of cardiovascular disease in older men: secondary analysis of observational study data. BMJ Open, 4(9), 1-9. [More Information]
  • Bell, K., Glasziou, P., Hayen, A., Irwig, L. (2014). Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality. Journal of Clinical Epidemiology, 67(2), 152-159. [More Information]

2013

  • Bell, K., Hayen, A., Irwig, L., Takahashi, O., Ohde, S., Glasziou, P. (2013). When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ, 346(7906), 1-8. [More Information]

2012

  • Hayden, A., Bell, K., Glasziou, P., Irwig, L. (2012). A counterargument to encounter frequency and target achievement: measurement variability. Archives of Internal Medicine, 172(4), 374-375. [More Information]
  • Bell, K., Hayen, A., McGeechan, K., Neal, B., Irwig, L. (2012). Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. European Journal of Preventive Cardiology, 19(6), 1474-1485. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Hochberg, M., Ensrud, K., Cummings, S., Bauer, D. (2012). The Potential Value of Monitoring Bone Turnover Markers Among Women on Alendronate. Journal of Bone and Mineral Research, 27(1), 195-201. [More Information]

2011

  • Bell, K., Kirby, A., Hayen, A., Irwig, L., Glasziou, P. (2011). Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ: British Medical Journal, 342(7791), 1-7. [More Information]
  • Turner, R., Bell, K., Morton, R., Hayen, A., Francken, A., Howard, K., Armstrong, B., Thompson, J., Irwig, L. (2011). Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 29(35), 4641-4646. [More Information]

2010

  • Hayen, A., Bell, K., Glasziou, P., Neal, B., Irwig, L. (2010). Monitoring Adherence to Medication by Measuring Change in Blood Pressure. Hypertension, 56(4), 612-616. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Fox, K., Remme, W., Asselbergs, F., van Gilst, W., MacMahon, S., Irwig, L., et al (2010). Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials. Hypertension, 56(3), 533-539. [More Information]
  • Bell, K., Irwig, L., Hayen, A., Macaskill, P., Craig, J. (2010). Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers. Pharmacoepidemiology and drug safety, 19(1), 99-105. [More Information]
  • Bell, K., Hayen, A., Irwig, L., Macaskill, P., Craig, J., Ensrud, K., Bauer, D. (2010). The Value of Routine BMD Monitoring After Starting Bisphosphonate Treatment. Journal of Bone and Mineral Research, 25(1), 173-174. [More Information]

2009

  • Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? A prospective study. Asia-Pacific Journal of Clinical Oncology, 5(4), 257-263. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Craig, J., Neal, B., Irwig, L. (2009). Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. Journal of Clinical Epidemiology, 62, 650-659. [More Information]
  • Lincz, L., Gupta, S., Wratten, C., Kilmurray, J., Nash, S., Seldon, M., O'Brien, P., Bell, K., Denham, J. (2009). Thrombin generation as a predictor of radiotherapy induced skin erythema. Radiotherapy and Oncology, 90(1), 136-140. [More Information]
  • Bell, K., Hayen, A., Macaskill, P., Irwig, L., Craig, J., Ensrud, K., Bauer, D. (2009). Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ: British Medical Journal, 338(7710), 1-5. [More Information]

2008

  • Bell, K., Craig, J., Irwig, L. (2008). Monitoring the initial response to treatment. In P Glasziou, L Irwig and J K Aronson (Eds.), Evidence-based Medical Monitoring:From Principles to Practice, (pp. 75-89). Oxford: Blackwell Publishers.
  • Bell, K., Irwig, L., Craig, J., Macaskill, P. (2008). Use of randomised trials to decide when to monitor response to new treatment. BMJ: British Medical Journal, 336, 361-365. [More Information]

2003

  • Bell, K., Wattie, M., Byth Wilson, K., Silvestrini, R., Clark, P., Stachowski, E., Benson, E. (2003). Procalcitonin: A marker of bacteraemia is SIRS. Anaesthesia and Intensive Care, 31(6), 629-636.

To update your profile click here. For support on your academic profile contact .